Rani Therapeutics Holdings, Inc. - 10-Q Filing
Rani Therapeutics reports Q3 2026 financial results featuring ongoing R&D and G&A expenses alongside complex equity structures including pre-funded warrants and restricted stock units.
Tickers: $RANI
Rani Therapeutics reports Q3 2026 financial results featuring ongoing R&D and G&A expenses alongside complex equity structures including pre-funded warrants and restricted stock units.
Tickers: $RANI